Data as of Apr 17
| +0.18 / +3.16%|
The 1 analysts offering 12-month price forecasts for Northwest Biotherapeutics Inc have a median target of 15.10, with a high estimate of 15.10 and a low estimate of 15.10. The median estimate represents a +156.80% increase from the last price of 5.88.
The current consensus among 2 polled investment analysts is to Buy stock in Northwest Biotherapeutics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.